Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Raderer

Showing results (181-190 of 264) with videos related to

Pageof 27
Sort By:
Blood|November 24, 2016
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphomaBarbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, et al.
Endocrine Pathology|March 12, 2025
Methylation Profiles Differ According to Clinical Characteristics in Well-Differentiated Neuroendocrine Tumors of the LungPhilipp Melhorn, Erwin Tomasich, Alissa Blessing, et al.
British Journal of Haematology|May 25, 2019
Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysisBarbara Kiesewetter, Wolfgang Lamm, Werner Dolak, et al.
European Journal of Clinical Investigation|May 18, 2012
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myelomaJohanna Atamaniuk, Andreas Gleiss, Edit Porpaczy, et al.
International Journal of Clinical and Health Psychology : IJCHP|June 6, 2022
Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatientsElisabeth L Zeilinger, Ingo W Nader, Wolfgang Wiedermann, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancerWerner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Investigative Radiology|April 12, 2018
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary ResultsMarius E Mayerhoefer, Ulrich Jaeger, Philipp Staber, et al.
Clinical Nuclear Medicine|September 21, 2016
Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 PatientsMarius E Mayerhoefer, Georgios Karanikas, Kurt Kletter, et al.
Scientific Reports|February 24, 2019
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patientsNoemi Pavo, Henrike Arfsten, Anna Cho, et al.
Pageof 27

Showing results (181-190 of 264) with videos related to

Sort By:
Pageof 27
Blood|November 24, 2016
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphomaBarbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, et al.
Endocrine Pathology|March 12, 2025
Methylation Profiles Differ According to Clinical Characteristics in Well-Differentiated Neuroendocrine Tumors of the LungPhilipp Melhorn, Erwin Tomasich, Alissa Blessing, et al.
British Journal of Haematology|May 25, 2019
Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysisBarbara Kiesewetter, Wolfgang Lamm, Werner Dolak, et al.
European Journal of Clinical Investigation|May 18, 2012
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myelomaJohanna Atamaniuk, Andreas Gleiss, Edit Porpaczy, et al.
International Journal of Clinical and Health Psychology : IJCHP|June 6, 2022
Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatientsElisabeth L Zeilinger, Ingo W Nader, Wolfgang Wiedermann, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancerWerner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Investigative Radiology|April 12, 2018
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary ResultsMarius E Mayerhoefer, Ulrich Jaeger, Philipp Staber, et al.
Clinical Nuclear Medicine|September 21, 2016
Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 PatientsMarius E Mayerhoefer, Georgios Karanikas, Kurt Kletter, et al.
Scientific Reports|February 24, 2019
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patientsNoemi Pavo, Henrike Arfsten, Anna Cho, et al.
Pageof 27